Rituximab Added to Treat Refractory Retroperitoneal Fibrosis Case
A case report describes the successful use of rituximab to treat refractory MPO-ANCA-positive retroperitoneal fibrosis after initial therapy failed.
A case report describes the successful use of rituximab to treat refractory MPO-ANCA-positive retroperitoneal fibrosis after initial therapy failed.
A study of 206 treatment-naïve patients with Sjögren's disease reveals that distinct serological markers correspond to specific glandular and extraglandular ...
A preliminary study found elevated expression of the long non-coding RNA lnc-DC in renal tissues from five patients with biopsy-proven ...
A comprehensive clinical review demonstrates that systemic lupus erythematosus significantly increases maternal and fetal complications, underscoring the critical necessity of ...
A systematic review of 38 observational and diagnostic accuracy studies indicates that salivary gland ultrasonography offers moderate-to-high diagnostic performance for ...
A retrospective cluster analysis of 500 patients identified two distinct severe tuberculosis subtypes with markedly different requirements for mechanical ventilation ...
A patient with severe relapsed and refractory lupus nephritis achieved durable clinical and renal remission following treatment with allogeneic CD19-targeted ...
A retrospective study identified seven patients with coexisting amyotrophic lateral sclerosis and primary Sjögren’s syndrome alongside shared, non-specific inflammatory transcriptomic ...
A two-year prospective cohort study found that tofacitinib therapy induces remission and restores CD4-positive regulatory T cell homeostasis in active ...
A cross-sectional study of 40 patients with systemic sclerosis found that nailfold capillaroscopy abnormalities are associated with primary heart involvement ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine